Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population

Quality of Life Research

Volumn 16, Issue 2, 2007, Pages 203-215

  Steel, Jennifer L ^a   Chopra, Kapil ^b   Olek, Marion C ^b   Carr, Brian I ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER THERAPY; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; EMOTION; FAMILY; FEMALE; FUNCTIONAL ASSESSMENT; HEPATOBILIARY PARAMETERS; HUMAN; INSTRUMENT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SAMPLE; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; WELLBEING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 33846161242     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-006-9111-2     Document Type: Article

References (32)

1. Harrison TJ. Viral hepatitis and primary liver cancer. In: Arrand JR, Harper DR (eds.Viruses and Human Cancer. Oxford: BIOS Scientific Publishers Limited, 1998.
2. Bonkovsky HL, Woolley JM, and the Concsensus Interferon Study Group (1999) Reduction of health related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 29(1):264-270.
3. Martin LM, Sheriddan MJ, Younossi ZM The impact of liver disease on health related quality of life: A review of the literature. Current Gasteroenterol Rep 2002; 4(1): 79-83.
4. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG Relation between tumor size, quality of life, and survival in patient with colorectal liver metastases. J Clin Oncol 1996;14(1): 171-175.
5. Pistevou-Gombaki K, Eleftheriadis N, Plataniotic GA, Sofroniadid I, Kouloulias VE Octreotide for palliative treatment of hepatic metastases from non-neuroendrocine primary tumours:Evaluation of quality of life using the EORTC QLQ-30 questionnaire. Palliat Med 2003; 17(3): 257-262.
6. Poon RTP, Fan ST, Yu WC, Lam BKY, Wong J A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg 2001; 136(6): 693-699.
7. Ueno S, Tanabe G, Nuruki K, Yoshidome S, Kubo F, Kihara K, Aoki D, Aikou T. Quality of life after hepatectomy in patients with hepatocellular carcinoma: Implications of change in hepatic protein synthesis. Hepato-Gastroenterology 2002; 49(44): 492-496.
8. Steel J.L., Geller D.A., Carr B.I. Proxy Ratings of Health Related Quality of Life in Patients with Hepatocellular Carcinoma. Qual Life Res 2005; 14: 1025-1033.
9. Steel J.L., Carr B.I., Baum A. Quality of life in patients diagnosed with primary hepatocellular carcinoma:Hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere®). Psycho-Oncol 2004; 13(2): 73-79.
10. Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol, in press.
11. Hefferman S, Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J The Functional Assessment of Cancer Therapy scale:Development and validation of the general measure. J Clin Oncol 1993; 11(3): 570-579.
12. Blazeby JM, Currie E, Zee BCY, Chie W-C, Poon RT, Garen OJ, on behalf of the EORTC Quality of Life Group. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 2004; 40(16): 2439-2444.
13. Pokros PJ, Shiffman ML, Schoff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatogology 2004; 40(6): 1450-1458.
14. Casanovas T, Vallejo G, Herdman M, Casado A, Ribas S, Rodriquez FE, Tremosa G, Menchon JM, Figueras J, Casais LA Validation of the Spanish version of the Liver Disease Quality of Life questionnaire in transplant patients. Transplant Proc 2003; 35(5): 1803-1805.
15. Plas SMvan der, Hansen BE, deBoer JB, Stijnen T, Passchier J, Man RAde, Schalm SW The Liver Disease Symptom Index 2.0:Validation of a disease specific questionnaire. Qual Life Res 2004; 13(8): 1469-1481.
16. Hauser W, Schnur M, Steder-Neukamm U, Muthny FA, Grandt D Validation of the German version of the Chronic Liver Disease Questionnaire. Eur J Gastroenterol Hepatol 2004; 16(6): 599-606.
17. Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Artinian L, Kim S, Lazarovici D, Jensen DM, Busuttil RW, Martin P Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. Am J Gasteroenterol 2000; 95(12): 3552-3365.
18. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC, and the Asian-Pacific Hepatocellular Carcinoma Trials Group. High dose tamoxifen in the treatment of inoperable hepatocellular carcinoma:A multicenter randomized controlled trial. Hepatology 2002; 36(5): 122-1226.
19. Brans B, Lambert B, DeNeule E, De Winter F, Van Belle S, Van Vlierberghe H, Hemptinne Bde, Dierckz RA Quality of life assessment in radionuclide therapy:A feasibility study of the EORTC QLQ-C30 questionnaire in palliative (131) I-lipiodol therapy. Eur J Nucl Med Mol Imaging 2002; 29(1): 1374-1379.
20. Hauser W, Holtmann G, Grandt D Determinants of health-related quality of life in patients with chronic liver disease. Clin Gasteroenterol Hepatol 2004; 2(2): 157-163.
21. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45(2): 295-300.
22. Younossi ZM, Boparai N, Price LL, Kiwi ML, McComrmick M, Guyatt G Health related quality life in chronic liver disease:the impact of the type and severity of disease. Am J Gastroenteronol 2001; 96(7): 199-205.
23. Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Brunetti N, DeSimone T, Zoli , M , Marchesini G Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis 2003; 35(1): 46-54.
24. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clinl Oncol 1993; 11(3): 570-579.
25. Webster K, Cella D, Yost , K The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 11-18.
26. Brucker PS, Yost K, Cashy J, Webster K, Cella D General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005; 28(2): 192-211.
27. Steel JL, Eton D, Cella D, Olek M, Carr BI. Measuring health related quality of life in patients with hepatobiliary carcinoma. Annals of Oncology 2005, in press.
28. Cronbach LJ Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-333.
29. Arguedas MR, DeLawrence TG, Mc Guire BM Influence of hepatic encephalopathy on health related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48(8): 1622-1626.
30. Zabora J., Brintzenhofeszoc K., Curbow B., Hooker C., Piantadosi S. The prevalence of psychological distress by cancer site. Psycho-Oncol 2001; 20: 19-28.
31. Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P, Roffi L Interferon-induced depression:prevalence and management. Dig Liver Dis 2005; 37(2): 102-107.
32. Park CK, Park SY, Kim ES, Park JH, Hyun DW, Yun YM, Jo CM, Tak WY, Kweon YO, Kim SK, CHoi YH, Park SG Assessment of quality of life and associated factors in patients with chronic viral liver disease. Korean J Hepatol 2003; 9(3): 212-221.